@article{52ad3ee51a70491fa4a593ff82e0a8be,
title = "Studying APOE ϵ4 Allele Dose Effects with a Univariate Morphometry Biomarker",
abstract = "Background: A univariate neurodegeneration biomarker (UNB) based on MRI with strong statistical discrimination power would be highly desirable for studying hippocampal surface morphological changes associated with APOE ϵ4 genetic risk for AD in the cognitively unimpaired (CU) population. However, existing UNB work either fails to model large group variances or does not capture AD induced changes. Objective: We proposed a subspace decomposition method capable of exploiting a UNB to represent the hippocampal morphological changes related to the APOE ϵ4 dose effects among the longitudinal APOE ϵ4 homozygotes (HM, N = 30), heterozygotes (HT, N = 49) and non-carriers (NC, N = 61). Methods: Rank minimization mechanism combined with sparse constraint considering the local continuity of the hippocampal atrophy regions is used to extract group common structures. Based on the group common structures of amyloid-β (Aβ) positive AD patients and Aβ negative CU subjects, we identified the regions-of-interest (ROI), which reflect significant morphometry changes caused by the AD development. Then univariate morphometry index (UMI) is constructed from these ROIs. Results: The proposed UMI demonstrates a more substantial statistical discrimination power to distinguish the longitudinal groups with different APOE ϵ4 genotypes than the hippocampal volume measurements. And different APOE ϵ4 allele load affects the shrinkage rate of the hippocampus, i.e., HM genotype will cause the largest atrophy rate, followed by HT, and the smallest is NC. Conclusion: The UMIs may capture the APOE ϵ4 risk allele-induced brain morphometry abnormalities and reveal the dose effects of APOE ϵ4 on the hippocampal morphology in cognitively normal individuals.",
keywords = "Effect size, magnetic resonance imaging, permutation t-test, radial distance, regions-of-interest, subspace decomposition",
author = "Gang Wang and Wenju Zhou and Deping Kong and Zongshuai Qu and Maowen Ba and Jinguang Hao and Tao Yao and Qunxi Dong and Yi Su and Reiman, {Eric M.} and Caselli, {Richard J.} and Kewei Chen and Yalin Wang",
note = "Funding Information: A univariate morphometry biomarker generation method is proposed based on subspace decomposition to effectively depict the hippocampal morphological changes induced by three levels of genetic risk for AD. The empirical results This work was partially supported by National Natural Science Foundation of China (62171209, 61772253, 61771231, 61872170, 61877065, 6187 3117, 81571234); Key Research and Development Program of Shandong Province (2019JZZY 010125); Key Project of Shandong Natural Science Foundation (ZR2020KF023); National Institute on Aging (R21AG065942, R01AG069453, and P30AG 072980), the National Institute for Biomedical Imaging and Bioengineering (R01EB025032), National Eye Institute (R01EY032125), National Institute of Dental & Craniofacial Research (R01DE030286), and the Arizona Alzheimer Consortium. Funding Information: Data collection and sharing for this project was funded by the Alzheimer{\textquoteright}s Disease Neuroimag-ing Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering, and through generous contributions from the following: AbbVie, Alzheimer{\textquoteright}s Association; Alzheimer{\textquoteright}s Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company Genentech, Inc.; Fujire-bio; GE Healthcare; IXICO Ltd.;Janssen Alzheimer Immunotherapy Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development LLC.; Lumosity; Lundbeck; Merck & Co., Inc.;Meso Scale Diagnostics, LLC.; Neu-roRx Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian Institutes of Health Research is providing funds to support The supplementary material is available in the electronic version of this article: https://dx.doi.org/ 10.3233/JAD-215149. Publisher Copyright: {\textcopyright} 2022 - IOS Press. All rights reserved.",
year = "2022",
doi = "10.3233/JAD-215149",
language = "English (US)",
volume = "85",
pages = "1233--1250",
journal = "Journal of Alzheimer's Disease",
issn = "1387-2877",
publisher = "IOS Press",
number = "3",
}